Read More Analyst Ratings Downgrades News Price Target Goldman Sachs Downgrades 10x Genomics to Sell, Lowers Price Target to $35 By Benzinga Newsdesk August 18, 6:10 AM Goldman Sachs analyst Matthew Sykes downgrades 10x Genomics (NASDAQ:TXG) from Neutral to Sell and lowers the price target from $55 to $35. TXG
Read More Analyst Color Analyst Ratings Biotech Downgrades Earnings General Health Care Movers News Penny Stocks Short Sellers Trading Ideas Analyst Downgrades Aravive: Grapples With Trial Setback, Strategic Alternatives By Vandana Singh August 22, 4:35 PM Monday, Aravive Inc (NASDAQ: ARAV) filed its quarterly 10Q ARAV
Read More Analyst Ratings Initiation News Price Target Goldman Sachs Initiates Coverage On Vertex with Buy Rating, Announces Price Target of $20 By Benzinga Newsdesk October 21, 5:29 AM Goldman Sachs analyst Adam Hotchkiss initiates coverage on Vertex (NASDAQ:VERX) with a Buy rating and announces Price Target of $20. VERX
Read More Earnings News Penny Stocks Tech Kopin Q1 Topline Beats Despite Weaker Industrial Segment Performance By Anusuya Lahiri May 11, 12:06 PM Kopin Corp (NASDAQ:KOPN) reported a first-quarter FY23 revenue decline of 7% year-on-year to $10.8 million, beating the consensus of $9.8… KOPN